These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 37821769)
1. A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations. Puszkiel A; Bousquet G; Stanke-Labesque F; Stocco J; Decq P; Chevillard L; Goutagny S; Declèves X Pharm Res; 2023 Nov; 40(11):2687-2697. PubMed ID: 37821769 [TBL] [Abstract][Full Text] [Related]
2. Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data. Wu S; Chang HY; Chowdhury EA; Huang HW; Shah DK AAPS J; 2024 Mar; 26(2):29. PubMed ID: 38443635 [TBL] [Abstract][Full Text] [Related]
3. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. Le Tilly O; Azzopardi N; Bonneau C; Desvignes C; Oberkampf F; Ezzalfani M; Ternant D; Turbiez I; Gutierrez M; Paintaud G Clin Pharmacol Ther; 2021 Jul; 110(1):210-219. PubMed ID: 33547646 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. Lu C; Zhang Y; Chen M; Zhong P; Chen Y; Yu J; Wu X; Wu J; Zhang J Antimicrob Agents Chemother; 2016 Nov; 60(11):6619-6625. PubMed ID: 27572392 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146 [TBL] [Abstract][Full Text] [Related]
6. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Cao Y; Balthasar JP; Jusko WJ J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115 [TBL] [Abstract][Full Text] [Related]
7. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies. Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Kirschbrown WP; Wang B; Nijem I; Ohtsu A; Hoff PM; Shah MA; Shen L; Kang YK; Alsina M; Girish S; Garg A Cancer Chemother Pharmacol; 2019 Sep; 84(3):539-550. PubMed ID: 31183514 [TBL] [Abstract][Full Text] [Related]
10. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Shah DK; Betts AM J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261 [TBL] [Abstract][Full Text] [Related]
11. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of AAV9 Mediated Trastuzumab Expression in Rat Brain Following Systemic and Local Administration. Chowdhury EA; Ahuja M; Wu S; Liu S; Huang HW; Kumar M; Sunkara KS; Ghobrial A; Chandran J; Jamier T; Perkinton M; Meno-Tetang G; Shah DK J Pharm Sci; 2024 Jan; 113(1):131-140. PubMed ID: 37659717 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282 [TBL] [Abstract][Full Text] [Related]
14. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. Cao Y; Jusko WJ J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin Chen X; Li C; Ewesuedo R; Yin D Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945 [TBL] [Abstract][Full Text] [Related]
16. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
17. Plasma and cerebrospinal fluid population pharmacokinetic modeling and simulation of meropenem after intravenous and intrathecal administration in postoperative neurosurgical patients. Li X; Wang X; Wu Y; Sun S; Chen K; Lu Y; Wang Q; Zhao Z Diagn Microbiol Infect Dis; 2019 Apr; 93(4):386-392. PubMed ID: 30638947 [TBL] [Abstract][Full Text] [Related]
18. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. Wang Y; Sawchuk RJ J Pharm Sci; 1995 Jul; 84(7):871-6. PubMed ID: 7562440 [TBL] [Abstract][Full Text] [Related]
19. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Braen AP; Perron J; Tellier P; Catala AR; Kolaitis G; Geng W Int J Toxicol; 2010; 29(3):259-67. PubMed ID: 20448258 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. Lamminsalo M; Piirainen P; Kokki H; Knibbe CAJ; Ranta VP; Välitalo P; Kokki M Expert Opin Drug Deliv; 2019 Jun; 16(6):649-656. PubMed ID: 31092024 [No Abstract] [Full Text] [Related] [Next] [New Search]